Dr. Mannis Talks About Emerging Treatments for Acute Myeloid Leukemia

Video

In Partnership With:

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses new methods of treatment for acute myeloid leukemia.

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses new methods of treatment for acute myeloid leukemia (AML).

In the last 6 to 9 months, 4 new drugs have been approved by the FDA. CPX-351 (Vyxeos) was approved as a liposomal version of 7+3 chemotherapy, which combines cytarabine and daunorubicin in a 5:1 molar ratio. In patients with secondary AML, therapy-related AML, or de novo AML with myelodysplasia-related changes, the drug was shown to improve overall survival (OS). OS almost doubled for patients receiving CPX-351 relative to 7+3 chemotherapy.

For patients with secondary AML or therapy-related AML, CPX-351 is the new standard of care for fit patients who are able to undergo intensive chemotherapy. Opposed to traditional chemotherapy agents, patients do not lose their hair as it is much less toxic than standard 7+3 chemotherapy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD